Preferences for antimuscarinic therapy for overactive bladder
Article first published online: 24 NOV 2010
© 2010 OXFORD OUTCOMES LTD
Volume 108, Issue 6, pages 868–873, September 2011
How to Cite
Swinburn, P., Lloyd, A., Ali, S., Hashmi, N., Newal, D. and Najib, H. (2011), Preferences for antimuscarinic therapy for overactive bladder. BJU International, 108: 868–873. doi: 10.1111/j.1464-410X.2010.09882.x
- Issue published online: 25 AUG 2011
- Article first published online: 24 NOV 2010
- Accepted for publication 1 September 2010
- 2Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). In AbramsP, CardozoL, KhouryS, WeinA eds, Incontinence, 4th edn. Comm 1. Paris: Health Publications Ltd. London, Editions 21, 2009: 35–112.
- 7The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388–95, , , , , .
- 10NICE. Urinary Incontinence: The Management of Urinary Incontinence in Women. NICE guideline. October 2006
- 14Benefit valuation in health economics. In Ian JBateman ed. Using Discrete Choice Experiments to Value Health and Health Care, Dordrecht: Springer, 2008: 13–46.
- 15Using discrete choice experiments to value healthcare programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2: 55–64.
- 22Cognitive Interviewing. London: Sage Publications, Ltd, 2005.
- 24Treatment of overactive bladder and incontinence in the elderly. Rev Urol 2002; 4: S38–43, .
- 25What does it mean to understand a risk? Evaluating risk comprehension. J Natl Cancer Inst 1999; 25: 15–20.